Articles producció científica> Medicina i Cirurgia

Adjustment of eculizimab dosage pattern in patients with atypical hemolytic uremic síndrome with suboptimal response to standard treatment pattern

  • Datos identificativos

    Identificador: imarina:6040509
    Handle: https://hdl.handle.net/20.500.11797/imarina6040509
    Autores:
    García Monteavaro C, Peralta Roselló C, Quiroga B, Baltar Martín JM, Castillo Eraso L, de Álvaro Moreno F, Martínez Vea A, Visus-Fernández de Manzanos MT.
    Resumen:
    In patients with atypical hemolytic uremic syndrome (aHUS), complement blocking by eculizumab rapidly halts the process of thrombotic microangiopathy and it is associated with clear long-term hematologic and renal improvements. Eculizumab treatment consists of a 4-week initial phase with weekly IV administration of 900 mg doses, followed by a maintenance phase with a 1,200 mg dose in the fifth week and every 14 ± 2 days thereafter. We present three patients with aHUS and suboptimal response to eculizumab treatment at the usual administration dosage who showed hematologic and renal improvements after an adjustment in the eculizumab treatment protocol.

  • Otros:

    Autor según el artículo: García Monteavaro C, Peralta Roselló C, Quiroga B, Baltar Martín JM, Castillo Eraso L, de Álvaro Moreno F, Martínez Vea A, Visus-Fernández de Manzanos MT.
    Departamento: Medicina i Cirurgia
    Autor/es de la URV: Castillo Eraso, Norma Lorena / Martínez Vea, Alberto
    Resumen: In patients with atypical hemolytic uremic syndrome (aHUS), complement blocking by eculizumab rapidly halts the process of thrombotic microangiopathy and it is associated with clear long-term hematologic and renal improvements. Eculizumab treatment consists of a 4-week initial phase with weekly IV administration of 900 mg doses, followed by a maintenance phase with a 1,200 mg dose in the fifth week and every 14 ± 2 days thereafter. We present three patients with aHUS and suboptimal response to eculizumab treatment at the usual administration dosage who showed hematologic and renal improvements after an adjustment in the eculizumab treatment protocol.
    Áreas temáticas: Nephrology
    Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
    Direcció de correo del autor: normalorena.castillo@urv.cat alberto.martinez@urv.cat
    Identificador del autor: 0000-0002-0819-8096
    Fecha de alta del registro: 2024-03-14
    Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
    Enlace a la fuente original: https://www.hindawi.com/journals/crin/2016/7471082/
    Referencia al articulo segun fuente origial: Case Rep Nephrol. 2016 7471082-7471082
    Referencia de l'ítem segons les normes APA: García Monteavaro C, Peralta Roselló C, Quiroga B, Baltar Martín JM, Castillo Eraso L, de Álvaro Moreno F, Martínez Vea A, Visus-Fernández de Manzanos (2016). Adjustment of eculizimab dosage pattern in patients with atypical hemolytic uremic síndrome with suboptimal response to standard treatment pattern. Case Rep Nephrol, 2016(), 7471082-7471082. DOI: 10.1155/2016/7471082
    URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
    DOI del artículo: 10.1155/2016/7471082
    Entidad: Universitat Rovira i Virgili
    Año de publicación de la revista: 2016
    Tipo de publicación: Journal Publications